Tetrapeptide analgesic - PVP Labs
Alternative Names: L-tyrosyl-D-arginyl-L-phenylalanylglycinamide; Taphalgin; TAPHALGIN®Latest Information Update: 07 Aug 2026
At a glance
- Originator PVP Labs
- Class Non-opioid analgesics; Peptides
- Mechanism of Action Calcium channel modulators; OPRM1 protein agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Postoperative pain
- Phase III Cancer pain
Most Recent Events
- 07 Aug 2026 PVP Labs plans to file an IND application with the US FDA for Postoperative pain in Q2 2027 (PVP Labs website, August 2026)
- 20 Mar 2026 Launched for Postoperative pain in Russia (SC), prior to March 2026
- 17 Mar 2026 Chemical structure information added.